Meningococcal polysaccharide vaccine group C
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Meningococcal polysaccharide vaccine group C
- meningococcal polysaccharide vaccine group c
- Meningococcal polysaccharide vaccine group c
- meningococcus c purified polysaccharides antigen conjugated
- Meningococcus c, purified polysaccharides antigen conjugated
- ATC classification codes
- J07AH07
Sources for recorded values
- ChEMBL ID
- CHEMBL2108795
- RxNorm IDs (RxCUI)
- 29503
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Meningococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004249
- Subject identifier
- D008589
Open Targets indications
- Condition identifier
- EFO_0004249
- Highest recorded phase
- 3
Trial references
- NCT06228586
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (51)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
- A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
- A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants
- A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
- A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
- Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
- Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
- Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
- Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001
- Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002
- Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
- Dose Comparison Study of Menactra® in US Children
- Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women
- Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
- Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.
In development for (1)
- Meningococcal infection Phase 3